Clene (CLNN) News
NASDAQ: CLNNHealth CareBiotechnology: Pharmaceutical PreparationsUSD
3.52+0.02 (+0.57%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
CLNN news summary
We found 4 recent headlines mentioning Clene (CLNN): 0 in the past week and 2 in the past 30 days, most often from Nasdaq, GlobeNewswire. For price context, CLNN is up 0.57% at $3.52. The most recent story, "Clene Inc. Reports Third Quarter 2026 Financial Results and Recent Operating Highlights", was published by Nasdaq on Nov 4, 2026.
Headlines link to the original publishers. MetaCap does not republish third-party articles.
Summary generated from market data by MetaCap's automated system. Methodology
Latest Clene headlines
- Clene Inc. Reports Third Quarter 2026 Financial Results and Recent Operating HighlightsClene Inc. announced its third quarter 2026 financial results and recent operating highlights. In October 2026, the company submitted a New Drug Application to the U.S. Food and Drug Administration…Nasdaq
- Clene Reports Third Quarter 2026 Financial Results and Recent Operating HighlightsSALT LAKE CITY, Nov. 04, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a late clinical-stage biopharmaceutical company focused on revolutionizing the treatment of neurodegenerative diseases,…GlobeNewswire
- Clene Seeks FDA Clearance For CNM-Au8 Following ALS Clinical Research(RTTNews) - Clene Inc. (CLNN), a clinical-stage biopharmaceutical company, announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) earlier in October,…NasdaqCLNN, SUN
- Clene Announces New Drug Application Submission to FDA for CNM-Au8 for the Treatment of ALSSALT LAKE CITY, Oct. 19, 2026 (GLOBE NEWSWIRE) -- Clene Inc. (Nasdaq: CLNN), a clinical-stage biotechnology company focused on revolutionizing the treatment of neurodegenerative diseases, announced…GlobeNewswire